Resources

Past Presentation

Buprenorphine Macrodosing | January 16, 2024

Date of Presentation: January 16, 2024

In this presentation. Dr. Jessica Gregg and Dr. James Gasper, provide an overview of ‘macro’ or ‘high dose’ induction of buprenorphine, including the theory behind the concept and the limited supporting data.

Recording:

Presented by:

Dr. Jessica Gregg, MD, PhD | Dr. James Gasper, PharmD, BCPP

Jessica Gregg, MD, PhD, received her undergraduate degree at Stanford University, her medical degree at the University of New Mexico, and a PhD in Medical Anthropology at Emory University. She began her medical career in primary care at Oregon Health and Science University (OHSU), where she co-founded the OHSU Department of Medicine’s Social Medicine curriculum in partnership with City Central Concern, a non-profit caring for individuals struggling with lack of housing and substance use disorders. She subsequently became the medical director for Central City Concern’s Hooper Detoxification and Stabilization Center, and eventually assumed the role of Senior Medical Director for Substance Use Disorder Services for the agency. She subsequently developed the HRBR clinic at OHSU, a low-threshold buprenorphine clinic, and in 2021, she became Chief Medical Officer for Fora Health in Portland, Oregon.

Dr. James Gasper, PharmD, BCPP, completed his Doctor of Pharmacy at the University of Colorado Health Sciences Center followed by a post-graduate residency at the Denver Veterans Affairs Medical Center and also in psychiatric pharmacy at the University of California San Francisco.  James spent the first 10 years of his career with the San Francisco Department of Public Health in both specialty mental health and substance use disorder treatment settings.  He helped establish buprenorphine in primary care and pharmacy-based methadone maintenance for the city’s indigent population.  

Since leaving San Francisco, James has relocated to the Sierra Nevada foothills of California. Using his past experience, he has helped close the gap in access to addiction treatment in his rural community by setting up primary care-based buprenorphine treatment programs locally. He is also a consultant for the National Clinician Consultation Center Substance Use Warmline, providing expertise to health care providers across the country.

 

Resources Provided:

Date added: January 2, 2024